Jun 02, 2018
The 2018 ASCO Annual Meeting, taking place June 1-5 in Chicago, brings together more than 32,000 oncology professionals from around the world to present and discuss the latest research in cancer treatment and patient care.
Major studies released today provide updates on Lynch syndrome, lung cancer, and advanced breast cancer.
New Targeted Therapy Slows Growth of Advanced Breast Cancer (Abstract LBA1006)
In a phase III clinical trial, a new targeted medicine, taselisib, combined with standard hormone therapy fulvestrant (Faslodex®), halted the growth of advanced breast cancer growth by 2 months longer than hormone therapy alone, and decreased the chance of cancer worsening by 30%.
Genomic Study Finds Lynch Syndrome Is Common Among People With MSI-High Tumors (Abstract LBA1509)
A genomic study of more than 15,000 tumor samples shows that people with tumors that have high microsatellite instability (MSI-H) – a genomic marker associated with a large number of genetic mutations in the tumor – are more likely to have Lynch syndrome, a hereditary condition that increases a person’s risk of developing many different types of cancer.
Matching Treatment to Genetic Changes in the Tumor Improves Survival Across Multiple Cancer Types (Abstract LBA2553)
Researchers conducted a retrospective analysis of consecutive, prospectively molecularly profiled patients with advanced cancer who participated in a large, personalized medicine trial. They found that using molecular tests of tumors to select targeted therapy resulted in slower cancer growth and prolonged survival across a diverse set of cancer types.
Blood Test Shows Potential as a Detection Tool for Early-Stage Lung Cancer (Abstract LBA8501)
An initial report from the large, ongoing Circulating Cell-Free Genome Atlas (CCGA) study provides preliminary evidence that a blood test may be able to detect early-stage lung cancer.
Adding Atezolizumab Immunotherapy to Chemotherapy Slows Growth of Advanced Squamous Lung Cancer (Abstract LBA9000)
Initial findings from a randomized phase III clinical trial show that patients with advanced squamous non-small-cell lung cancer (NSCLC) benefit more from initial treatment with PD-L1 targeted immunotherapy atezolizumab (Tecentriq®) and chemotherapy than from chemotherapy alone -- 29% had a reduced risk of disease worsening or death compared with those who received chemotherapy alone.
For more information about ASCO and the 2018 ASCO Annual Meeting, visit am.asco.org.